http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-112018015237-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a8542a6540f7a430496e157235639135 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12R2001-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-095 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H15-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7024 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N1-205 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H15-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7024 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 |
| filingDate | 2017-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b93669a7d214cee6a41e94ca0a81e7b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d2756454f22b601839571154c898079 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e778585b6b5fc8c840eb504402610637 |
| publicationDate | 2018-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-112018015237-A2 |
| titleOfInvention | modified hexa-acyl neisseria lps |
| abstract | The present invention relates to a neisserial lps having a chemical fraction of the hexa-acylated lipid, wherein the chemical fraction of the hexa-acylated lipid is modified compared to the chemical fraction of the lipid to one of the hexa-acylated lipid. wild type wherein it comprises a palmitoleoyl instead of a lauryl secondary acyl chain at the non-reducing end of the lipid a chemical fraction. The invention further relates to mixtures of hexa-acylated lps with the corresponding penta-acylated lps, which does not have a glucosamine secondary acyl chain at the non-reducing end of the lipid a chemical fraction. The invention also relates to neisserial bacteria that have been genetically engineered to reduce expression of the endogenous lpxl1 gene and to introduce expression of a heterologous thermosensitive lpxp gene to produce the hexa and penta-acylated lps. By selecting the time and / or temperature at which the bacterium is proliferated, it is feasible to increase or decrease the amount of lipid to hexa-acylated structure relative to the penta-acylated structure, and thereby modulate the agonist activity of the bacterium. of the neisserial lps of the invention at the exact level of activity required for a particular immunotherapeutic approach. |
| priorityDate | 2016-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 25.